Reviewing Compugen (CGEN) and Ohr Pharmaceuticals (OHRP)
Compugen (NASDAQ: CGEN) and Ohr Pharmaceuticals (NASDAQ:OHRP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.
Volatility and Risk
Compugen has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Ohr Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.
This table compares Compugen and Ohr Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ohr Pharmaceuticals||N/A||N/A||-$25.76 million||($0.70)||-2.20|
Ohr Pharmaceuticals has lower revenue, but higher earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than Ohr Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Compugen and Ohr Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
18.5% of Compugen shares are held by institutional investors. Comparatively, 8.4% of Ohr Pharmaceuticals shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 17.4% of Ohr Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a summary of recent ratings and recommmendations for Compugen and Ohr Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Compugen presently has a consensus price target of $14.00, suggesting a potential upside of 460.00%. Ohr Pharmaceuticals has a consensus price target of $8.50, suggesting a potential upside of 451.95%. Given Compugen’s higher probable upside, analysts clearly believe Compugen is more favorable than Ohr Pharmaceuticals.
Compugen Company Profile
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Ohr Pharmaceuticals Company Profile
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.